Bristol-Myers Squibb (BMY) Tops Q1 EPS by 1c, Maintains EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Bristol-Myers Squibb Reports First Quarter Financial Results
April 25, 2019 6:59 AM EDTIncreases First Quarter Revenues 14% to $5.9 Billion Posts First Quarter GAAP EPS of $1.04 and Non-GAAP EPS of $1.10 Announces Shareholder Approval of Celgene Acquisition Presents Important New Data at American Association for Cancer Research and American College of Cardiology Annual Meetings Reaffirms Non-GAAP EPS Guidance Range of $4.10-$4.20 and Increases GAAP EPS Guidance Range to $3.84-$3.94
NEW YORK--(BUSINESS WIRE)--... More
